Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.BGNE · Entity 2168 | CMO, Immuno-oncology | December 17, 2018 | December 19, 2018 |
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | EVP, Chief Development Officer | March 16, 2023 | March 20, 2023 |
| EXELIXIS, INC.EXEL · Entity 3386 | EVP Prod Dev & Med Aff & CMO | May 15, 2025 | May 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date December 17, 2018 · Filed December 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2018-12-18 transaction · row 15
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
14 source rowsRow 2 · 2018-12-17 · Exercise / conversion · Acquired 9,859 · Balance 9,859 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The exercise price is represented in American Depositary Shares. Row 3 · 2018-12-17 · Sale · Disposed 900 · Balance 8,959 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.16 to $131.1599, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Row 4 · 2018-12-17 · Sale · Disposed 2,700 · Balance 6,259 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.38 to $132.3799, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Row 5 · 2018-12-17 · Sale · Disposed 1,700 · Balance 4,559 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.42 to $133.4199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Row 6 · 2018-12-17 · Sale · Disposed 1,005 · Balance 3,554 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.43 to $134.4299, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Row 7 · 2018-12-17 · Sale · Disposed 778 · Balance 2,776 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.60 to $135.5999, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Row 8 · 2018-12-17 · Sale · Disposed 2,296 · Balance 480 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.61 to $136.6099, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Row 9 · 2018-12-17 · Sale · Disposed 480 · Balance 0 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.65 to $137.6499, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Row 10 · 2018-12-18 · Exercise / conversion · Acquired 10,141 · Balance 10,141 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The exercise price is represented in American Depositary Shares. Row 11 · 2018-12-18 · Sale · Disposed 1,631 · Balance 8,510 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.01 to $132.0099, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Row 12 · 2018-12-18 · Sale · Disposed 1,897 · Balance 6,613 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.22 to $133.2199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Row 13 · 2018-12-18 · Sale · Disposed 2,402 · Balance 4,211 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.32 to $134.3199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Row 14 · 2018-12-18 · Sale · Disposed 3,600 · Balance 611 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.37 to $135.3699, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Row 15 · 2018-12-18 · Sale · Disposed 611 · Balance 0 F1: Each American Depositary Share represents 13 Ordinary Shares. F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.40 to $136.3999, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.24 · Expires 2026-08-21 | Direct | 951,833 |
Reported balance
After 2018-12-17 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2018-12-17 · Exercise / conversion · Disposed 128,167 · Balance 951,833 F16: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F17: These securities vest over a four-year period as follows: 25% on the first anniversary of August 22, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.24 · Expires 2026-08-21 | Direct | 820,000 |
Reported balance
After 2018-12-18 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2018-12-18 · Exercise / conversion · Disposed 131,833 · Balance 820,000 F16: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F17: These securities vest over a four-year period as follows: 25% on the first anniversary of August 22, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 194,569 |
Reported balance
Holding disclosure · report date 2018-12-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 194,569 |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share represents 13 Ordinary Shares.
F2: The exercise price is represented in American Depositary Shares.
F3: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.16 to $131.1599, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.38 to $132.3799, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.42 to $133.4199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.43 to $134.4299, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.60 to $135.5999, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.61 to $136.6099, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.65 to $137.6499, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.01 to $132.0099, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.
F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.22 to $133.2199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.
F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.32 to $134.3199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.
F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.37 to $135.3699, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.
F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.40 to $136.3999, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price.
F16: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.
F17: These securities vest over a four-year period as follows: 25% on the first anniversary of August 22, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events.
CytomX Therapeutics, Inc.
Report date March 16, 2023 · Filed March 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,433 |
Reported balance
After 2023-03-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-16 · Sale · Disposed 4,257 · Balance 58,433 F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units. F2: Includes 30,000 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units.
F2: Includes 30,000 restricted stock units.
EXELIXIS, INC.
Report date May 15, 2025 · Filed May 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 465,393 |
Last balance in matching sequence
After 2025-05-16 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2025-05-15 · Tax withholding · Disposed 8,303 · Balance 498,169 F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded February 23, 2024. F2: Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Row 2 · 2025-05-16 · Exercise / conversion · Acquired 40,000 · Balance 538,169 F2: Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Row 3 · 2025-05-16 · Sale · Disposed 72,776 · Balance 465,393 F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $45.08 to $46.44. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. F2: Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.75 · Expires 2030-08-23 | Direct | 120,000 |
Reported balance
After 2025-05-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-16 · Exercise / conversion · Disposed 40,000 · Balance 120,000 F4: The option, representing the right to purchase a total of 160,000 shares of Common Stock, 40,000 shares became exercisable on August 24, 2024 and the remainder will become fully exercisable on August 24, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded February 23, 2024.
F2: Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock.
F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $45.08 to $46.44. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4: The option, representing the right to purchase a total of 160,000 shares of Common Stock, 40,000 shares became exercisable on August 24, 2024 and the remainder will become fully exercisable on August 24, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2025 Filed May 17, 2025 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $21.75 | $0.00 |
DisclosureSEC source: 0000939767-25-000076 · wk-form4_1747443419.xml · derivative · entry 4 Peterson Amy C. · CIK 0001682735 · EVP Prod Dev & Med Aff & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 40,000 shares Expires 2030-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 160,000 shares of Common Stock, 40,000 shares became exercisable on August 24, 2024 and the remainder will become fully exercisable on August 24, 2027. Read SEC document |
| May 16, 2025 Filed May 17, 2025 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 72,776 | $45.47 | $3,309,124.72 |
DisclosureSEC source: 0000939767-25-000076 · wk-form4_1747443419.xml · nonDerivative · entry 3 Peterson Amy C. · CIK 0001682735 · EVP Prod Dev & Med Aff & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,393 F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $45.08 to $46.44. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. F2 · balance_after: Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| May 16, 2025 Filed May 17, 2025 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $21.75 | $870,000.00 |
DisclosureSEC source: 0000939767-25-000076 · wk-form4_1747443419.xml · nonDerivative · entry 2 Peterson Amy C. · CIK 0001682735 · EVP Prod Dev & Med Aff & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 538,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| May 15, 2025 Filed May 17, 2025 00:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 8,303 | $44.65 | $370,728.95 |
DisclosureSEC source: 0000939767-25-000076 · wk-form4_1747443419.xml · nonDerivative · entry 1 Peterson Amy C. · CIK 0001682735 · EVP Prod Dev & Med Aff & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 498,169 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded February 23, 2024. F2 · balance_after: Includes 453,166 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and performance-based restricted stock units ("PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each PSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| March 31, 2025 Filed Mar 31, 2025 23:43 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 159,383 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-25-000055 · wk-form4_1743464617.xml · nonDerivative · entry 1 Peterson Amy C. · CIK 0001682735 · EVP Prod Dev & Med Aff & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506,472 F1 · shares: Represents an award of performance-based restricted stock units (each, a "PSU") that was granted to the Reporting Person on the Transaction Date pursuant to the 2017 Equity Incentive Plan. Each PSU represents a contingent right to receive one share of Exelixis, Inc. common stock ("Common Stock"). The PSUs vest upon satisfaction of both (i) a performance-based condition requiring the volume-weighted average closing price of the Common Stock to equal or exceed $60 per share for any consecutive 90-calendar-day period during a five-year performance period, and (ii) a service-based condition requiring employment through the fifth anniversary of the grant date (except in the event of certain qualifying terminations of employment). F2 · balance_after: Includes 473,696 shares of Common Stock that will be issued to the Reporting Person upon the vesting of restricted stock units (each, an "RSU") and the PSUs. Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| February 26, 2025 Filed Mar 1, 2025 01:34 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 52,192 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-25-000040 · wk-form4_1740792891.xml · nonDerivative · entry 1 Peterson Amy C. · CIK 0001682735 · EVP Prod Dev & Med Aff & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,089 F1 · security: Represents shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. F2 · date: The RSUs were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 1/4th of the original number of shares subject to the RSU award on May 15, 2026 and thereafter as to 1/4th of the original number of shares subject to the RSU award on each May 15th until fully vested. F3 · balance_after: Includes 314,313 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs. Read SEC document |
| November 15, 2024 Filed Nov 20, 2024 01:02 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 27,224 | $35.05 | $954,201.20 |
DisclosureSEC source: 0000939767-24-000158 · wk-form4_1732064553.xml · nonDerivative · entry 1 Peterson Amy C. · CIK 0001682735 · EVP Prod Dev & Med Aff & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,897 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded August 24, 2023. F2 · balance_after: Includes 262,121 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs. Each RSU is the economic equivalent of one share of Common Stock. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:59 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 82,121 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-24-000035 · wk-form4_1709078340.xml · nonDerivative · entry 1 Peterson Amy C. · CIK 0001682735 · EVP Prod Dev & Med Aff & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 322,121 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2025 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 322,121 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 23:40 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 160,000 | $0.00 Strike: $21.75 | $0.00 |
DisclosureSEC source: 0000939767-23-000098 · wk-form4_1693006836.xml · derivative · entry 2 Peterson Amy C. · CIK 0001682735 · EVP Prod Dev & Med Aff & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2030-08-23 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 23:40 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-23-000098 · wk-form4_1693006836.xml · nonDerivative · entry 1 Peterson Amy C. · CIK 0001682735 · EVP Prod Dev & Med Aff & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on November 15, 2024 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each November 15th until fully vested. F3 · balance_after: Includes 240,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 22:43 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 4,257 | $1.98 | $8,424.60 |
DisclosureSEC source: 0001140361-23-012614 · form4.xml · nonDerivative · entry 1 Peterson Amy C. · CIK 0001682735 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,433 F1 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes 30,000 restricted stock units. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:11 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 7,463 | $1.42 | $10,612.39 |
DisclosureSEC source: 0001567619-22-014301 · doc1.xml · nonDerivative · entry 2 Peterson Amy C. · CIK 0001682735 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,690 F4 · kind: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer. F2 · balance_after: Includes 40,000 restricted stock units. Read SEC document |
| July 19, 2022 Filed Jul 21, 2022 20:11 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-014301 · doc1.xml · nonDerivative · entry 1 Peterson Amy C. · CIK 0001682735 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,153 F1 · kind: Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested. F2 · balance_after: Includes 40,000 restricted stock units. F3 · balance_after: Reflects the adjusted total which includes the purchase of 3,732 shares under the Cytomx Therapeutics Employee Stock Purchase Plan on May 31, 2022. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 21:53 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001567619-22-002525 · doc1.xml · derivative · entry 2 Peterson Amy C. · CIK 0001682735 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-02-01 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 21:53 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-002525 · doc1.xml · nonDerivative · entry 1 Peterson Amy C. · CIK 0001682735 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,421 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on March 15 of each year, with the first 1/4th vesting on March 15, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 40,000 RSUs. Read SEC document |
| October 24, 2021 Filed Oct 26, 2021 20:26 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantPerformance Stock Units (PSUs) · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-018718 · doc1.xml · derivative · entry 2 Peterson Amy C. · CIK 0001682735 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date. F2 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date. F2 · derivative.expiration_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone within 1 year from grant date and 50% of the PSUs vest upon achievement of a certain performance-based milestone within 2 years from grant date. Read SEC document |
| October 24, 2021 Filed Oct 26, 2021 20:26 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.34 | $0.00 |
DisclosureSEC source: 0001567619-21-018718 · doc1.xml · derivative · entry 1 Peterson Amy C. · CIK 0001682735 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-10-23 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from October 24, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| May 31, 2021 Filed Jun 8, 2021 17:07 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 3,320 | $6.09 | $20,205.52 |
DisclosureSEC source: 0001567619-21-011806 · doc1.xml · nonDerivative · entry 1 Peterson Amy C. · CIK 0001682735 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,421 F1 · kind: 3,320 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:07 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $7.85 | $0.00 |
DisclosureSEC source: 0001567619-21-005402 · doc1.xml · derivative · entry 1 Peterson Amy C. · CIK 0001682735 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from February 26, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| November 30, 2020 Filed Dec 7, 2020 21:59 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantCommon Stock | 3,101 | $6.39 | $19,821.59 |
DisclosureSEC source: 0001567619-20-020709 · doc1.xml · nonDerivative · entry 1 Peterson Amy C. · CIK 0001682735 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,101 F1 · kind: 3,101 shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 23:38 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0001567619-20-004346 · doc1.xml · derivative · entry 1 Peterson Amy C. · CIK 0001682735 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 23:01 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001567619-19-019675 · doc1.xml · derivative · entry 1 Peterson Amy C. · CIK 0001682735 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-10-14 F1 · derivative.exercise_date: The shares subject to the Inducement Option Award will vest and become exercisable as to 25% of the total number of shares subject to the option on October 14, 2020 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 131,833 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · derivative · entry 17 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 820,000 Underlying: Ordinary Shares · 131,833 shares Expires 2026-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F16 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F17 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of August 22, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 611 | $135.54 | $82,816.28 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · nonDerivative · entry 15 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.40 to $136.3999, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,600 | $134.81 | $485,315.64 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · nonDerivative · entry 14 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 611 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.37 to $135.3699, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,402 | $133.88 | $321,585.04 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · nonDerivative · entry 13 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,211 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.32 to $134.3199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,897 | $132.70 | $251,735.31 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · nonDerivative · entry 12 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,613 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.22 to $133.2199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,631 | $131.74 | $214,859.79 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · nonDerivative · entry 11 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,510 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.01 to $132.0099, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 10,141 | $29.10 | $295,103.10 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · nonDerivative · entry 10 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · price: The exercise price is represented in American Depositary Shares. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 128,167 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · derivative · entry 16 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 951,833 Underlying: Ordinary Shares · 128,167 shares Expires 2026-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F16 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F17 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of August 22, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 480 | $136.93 | $65,726.40 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · nonDerivative · entry 9 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.65 to $137.6499, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,296 | $136.24 | $312,817.60 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · nonDerivative · entry 8 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.61 to $136.6099, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 778 | $135.04 | $105,064.70 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · nonDerivative · entry 7 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,776 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.60 to $135.5999, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,005 | $133.81 | $134,478.55 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · nonDerivative · entry 6 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,554 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.43 to $134.4299, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,700 | $132.91 | $225,953.29 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · nonDerivative · entry 5 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,559 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.42 to $133.4199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,700 | $131.80 | $355,852.44 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · nonDerivative · entry 4 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,259 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.38 to $132.3799, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 900 | $130.37 | $117,331.02 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · nonDerivative · entry 3 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,959 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.16 to $131.1599, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 23:34 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 9,859 | $29.10 | $286,896.90 |
DisclosureSEC source: 0001651308-18-000018 · wf-form4_154526243150998.xml · nonDerivative · entry 2 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · price: The exercise price is represented in American Depositary Shares. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 156,871 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · derivative · entry 27 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,080,000 Underlying: Ordinary Shares · 156,871 shares Expires 2026-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F24 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F25 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of August 22, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $121.56 | $12,156.00 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 24 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F23 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.56 to $122.5599, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 109 | $117.61 | $12,819.56 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 23 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F22 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.84 to $117.8399, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 500 | $116.56 | $58,281.15 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 22 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F21 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.82 to $116.8199, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 700 | $114.96 | $80,472.00 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 21 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 709 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.63 to $115.6299, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,173 | $113.92 | $133,630.04 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 20 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,409 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.63 to $114.6299, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,527 | $113.03 | $285,632.37 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 19 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,582 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.61 to $113.6099, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 4,000 | $112.18 | $448,720.40 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 18 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,109 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.61 to $112.6099, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,958 | $111.10 | $328,637.65 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 17 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,109 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.50 to $111.4999, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 12,067 | $29.10 | $351,149.70 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 16 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · price: The exercise price is represented in American Depositary Shares. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 171,886 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · derivative · entry 26 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,236,871 Underlying: Ordinary Shares · 171,886 shares Expires 2026-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F24 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F25 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of August 22, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 15:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $125.97 | $12,597.00 |
DisclosureSEC source: 0001682735-18-000003 · wf-form4_154212240992906.xml · nonDerivative · entry 15 Peterson Amy C. · CIK 0001682735 · CMO, Immuno-oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.97 to $126.9699, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.